“Asthma is the most prevalent chronic respiratory disease in the world, with a substantial health and economic impact on patients. Around 358 million people suffered from asthma worldwide in 2015, causing 400,000 deaths,” Mohamed Awad Tageldin, Professor of Pulmonology at Ain Shams University, said.
Novartis Pharma S.A.E. (Novartis Egypt) held a press conference to announce the introduction of the first fixed dose combination triple therapy in one device for asthma in Egypt, with the goal of offering patients better control of their condition and improving their quality of life. Renowned respiratory and pulmonology experts were invited to discuss the …
Novartis has also collaborated with the ministry to run Egypt’s first coronavirus awareness seminar in March, that brought together over 5,600 multi-specialty doctors to discuss the latest developments on the pandemic.
Company commits to providing 130 million doses of hydroxychloroquine drug for treatment protocol
